The importance of determining the limit of detection of non-invasive prenatal testing methods

Prenat Diagn. 2016 Apr;36(4):304-11. doi: 10.1002/pd.4780. Epub 2016 Feb 21.

Abstract

Objective: Several non-invasive prenatal testing (NIPT) methods, which analyze circulating fetal cell-free DNA (cfDNA) in maternal plasma, suggest a fetal fraction (FF) ≥ 4% for a reportable result, with the assumption that fetal aneuploidies may not be detectable at lower FF. This study determined the actual limit of detection (LOD) of a massively parallel sequencing-based NIPT method and evaluated its performance in testing samples with low FF.

Method: An experimental model, involving the creation of artificial plasma mixtures with a final aneuploid FF ranging from 1% to 4%, simulated samples at different proportions of fetal cfDNA. We then analyzed 7103 blood samples, from pregnant women undergoing NIPT, to assess the impact of low FF on the performance of cfDNA testing.

Results: Detection of common aneuploidies in samples with an FF as low as 2% is well within the ability of this technology. Of 105 pregnancies confirmed chromosomally abnormal, 25 (23.8%) involving a 2% < FF < 4% were consistently detected. These high-risk pregnancies would have not been identified using the suggested 4% FF cut-off.

Conclusion: This study underscores the importance of determining the actual LOD for each specific NIPT methodology. It may reduce the incidence of test cancelations and shorten the time required for the diagnosis of aneuploidy. © 2016 John Wiley & Sons, Ltd.

MeSH terms

  • Adult
  • Aneuploidy*
  • Cell-Free System
  • Chromosome Disorders / diagnosis
  • Chromosomes, Human, Pair 13
  • Chromosomes, Human, Pair 18
  • DNA / blood
  • Down Syndrome / diagnosis
  • Female
  • Genetic Testing / methods*
  • Genetic Testing / standards
  • High-Throughput Nucleotide Sequencing*
  • Humans
  • Limit of Detection*
  • Maternal Serum Screening Tests / methods*
  • Maternal Serum Screening Tests / standards
  • Middle Aged
  • Pregnancy
  • Retrospective Studies
  • Sensitivity and Specificity
  • Trisomy / diagnosis
  • Trisomy 13 Syndrome
  • Trisomy 18 Syndrome

Substances

  • DNA